Article
Counteracting CAR T cell dysfunction
9 Nov 2020
Abstract excerpt
In spite of high rates of complete remission following chimeric antigen receptor (CAR) T cell therapy, the efficacy of this approach is limited by generation of dysfunctional CAR T cells in vivo, conceivably induced by immunosuppressive tumor microenvironment (TME) and excessive antigen exposure. Exhaustion and senescence are two critical dysfunctional states that impose a pivotal hurdle for successful CAR T cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
